至2040年澳大利亚成人与儿童关节炎负担预测:一项人群水平预测研究
该研究基于澳大利亚2022年国家健康调查和2021年人口普查的患病率数据,结合国家人口预测,预测至2040年澳大利亚关节炎、骨关节炎、类风湿关节炎及幼年特发性关节炎的人群规模与卫生系统支出。骨关节炎和类风湿关节炎的年龄标化率在男女中均预计上升。
核心结论
- 利用最新国家级数据,本研究对澳大利亚关节炎的沉重负担(人群规模和医疗费用)做出了当代预测,强调需要资源充足的卫生服务以确保及时、高价值的照护。
研究设计与样本
- 这是一项针对澳大利亚的人群水平预测研究,关节炎、骨关节炎和类风湿关节炎患病率数据来自澳大利亚统计局2022年国家健康调查,幼年特发性关节炎患病率来自2021年人口普查数据。
- 将年龄别和性别别患病率应用于国家人口预测,预测2025、2030、2035和2040年的患病人群;基础分析采用中等人口增长,敏感性分析考虑低和高增长情景。
- 卫生系统支出数据来自澳大利亚卫生与福利研究所,外推至基础情景预测年份并折算为未来澳元;一位关节炎消费者研究者和澳大利亚关节炎消费者咨询小组成员审阅了负担估计。
主要发现
- 骨关节炎年龄标化率预计男性从2025年的6.28%升至2040年的7.03%,女性从10.82%升至12.18%;类风湿关节炎年龄标化率预计男性从1.56%升至1.75%,女性从2.62%升至2.94%。
- 幼年特发性关节炎儿童和青少年人数预计变化不大(2040年估计为8500人)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Understanding how many people could be living with arthritis in the future is essential for planning health service needs and national health workforce requirements, and for arthritis advocacy and policy development. This study aimed to forecast the size of different populations with arthritis in Australia and associated health system expenditure, up to the year 2040. METHODS: In this population-level forecasting study for Australia, prevalence data for arthritis, osteoarthritis, and rheumatoid arthritis were obtained from the Australian Bureau of Statistics 2022 National Health Survey. Prevalence rates for juvenile idiopathic arthritis were sourced from 2021 Census data. Overall, age-specific and sex-specific prevalence data were applied to national population projections to forecast arthritis, osteoarthritis, rheumatoid arthritis, and juvenile idiopathic arthritis populations for 2025, 2030, 2035, and 2040. The base case analysis considered medium population growth; sensitivity analyses considered low and high growth scenarios. Health system expenditure data from the Australian Institute of Health and Welfare were extrapolated to base case projections for the years 2025, 2030, 2035, and 2040, and were then inflated to future dollars. To understand the broader context and implications of our projections through the lens of lived experience, an arthritis consumer researcher and members of the Arthritis Australia Consumer Advisory Panel reviewed the arthritis burden estimates. FINDINGS: With population growth and ageing, 5·39 million (95% CI 5·19-5·58) people are projected to have arthritis in Australia in 2040, representing an increase of 31% from 4·11 million (3·95-4·27) in 2025. By 2040, 3·11 million (2·99-3·23) people are expected to have osteoarthritis, 749 000 (652 000-846 000) are expected to have rheumatoid arthritis, and about 8500 children and adolescents are expected to have juvenile idiopathic arthritis. The age-standardised rate of osteoarthritis is forecast to increase for males from 6·28% in 2025 to 7·03% in 2040, and for females from 10·82% to 12·18% over this period. The age-standardised rate of rheumatoid arthritis is forecast to increase for males from 1·56% in 2025 to 1·75% in 2040, and for females from 2·62% in 2025 to 2·94% in 2040. Little change is anticipated in the number of children and adolescents with juvenile idiopathic arthritis (estimated at 8500 individuals in 2040). Based on current spending levels of AU$2100 per person with osteoarthritis and $1918 per person with rheumatoid arthritis, annual health system expenditure for osteoarthritis and rheumatoid arthritis is conservatively forecast to exceed AU$11·92 billion by 2040. INTERPRETATION: Using the latest national-level data, this study has generated contemporary projections of the substantial burden of arthritis (both population size and health-care costs) in Australia. These projections underscore the importance of well-resourced health services that can capably deliver timely, high-value care to a growing number of people with arthritis. FUNDING: Arthritis Australia and National Health and Medical Research Council.
引用
- Ackerman IN, Gorelik A, Berkovic D, et al. The projected burden of arthritis among adults and children in Australia to the year 2040: a population-level forecasting study. Lancet Rheumatol. 2024. PMID: 39647490. doi:10.1016/S2665-9913(24)00247-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。